Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02956486 · ClinicalTrials.gov registry record · Phase 3
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
A Phase 3 study, sponsored by Eisai Co..
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,212
- Enrollment target
NCT02956486 is a Phase 3 study that was terminated before completion, run by Eisai Co.. The registered enrollment target is 2,212 participants.
The verdict
NCT02956486, a Phase 3 study, was terminated before completion, sponsored by Eisai Co..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,212 participants
- Enrollment target
Study Summary
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Interventions
- DRUG Placebo
- DRUG Elenbecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,212 participants |
| Start Date | 2016-10-20 |
| Est. Completion | 2020-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02956486
The ClinicalTrials.gov registry entry for NCT02956486 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02956486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02956486 about?
NCT02956486 is a clinical study titled "A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease". The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, plac...
What is the current status of trial NCT02956486?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,212 participants. The study started on 2016-10-20. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT02956486?
The interventions under investigation include: Placebo (DRUG), Elenbecestat (DRUG).
Who is sponsoring clinical trial NCT02956486?
This trial is sponsored by Eisai Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.